Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Polycystic ovaries-urethral sphincter dysfunction syndrome is characterized by urinary retention and incomplete emptying of the bladder associated with abnormal electromyographic activity. It has been described in 33 women, 14 of whom also had polycystic ovaries.
Features include common findings: Polycystic ovaries, Abnormality of the urethra, Abnormal electrical muscle activity (EMG) (emg abnormality), and Dysuria; and sometimes findings: Urinary retention, Oligomenorrhea, Hirsutism, and Acne. 12 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 2 | Urinary retention, Urinary incontinence |
Phenotype severity distribution: 4 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for polycystic ovaries-urethral sphincter dysfunction syndrome.
17 publications have been identified in PubMed for polycystic ovaries-urethral sphincter dysfunction syndrome. Research spans Review / Meta-Analysis (35%), Case Report / Case Series (35%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 | 35% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:49 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Lab test results |
1 |
Abnormal electrical muscle activity (EMG) (emg abnormality) |
Hormones | 1 | Amenorrhea |
Patient case studies |
6 |
35% |
Clinical study results | 2 | 12% |
Disease patterns and progression | 2 | 12% |
Other research | 1 | 6% |
McConnell-Trevillion A (2026). [PMID: 42244907](https://pubmed.ncbi.nlm.nih.gov/42244907/). *Front Urol*. [Case Report / Case Series]
Spazzapan M (2026). [PMID: 42221686](https://pubmed.ncbi.nlm.nih.gov/42221686/). *Ther Adv Urol*. [Case Report / Case Series]
Kogovsek U (2026). [PMID: 42064257](https://pubmed.ncbi.nlm.nih.gov/42064257/). *Urol Case Rep*. [Case Report / Case Series]
Dequirez PL (2025). [PMID: 38289258](https://pubmed.ncbi.nlm.nih.gov/38289258/). *Neurourol Urodyn*. [Review / Meta-Analysis]
Bouchard B (2025). [PMID: 38108542](https://pubmed.ncbi.nlm.nih.gov/38108542/). *Neurourol Urodyn*. [Review / Meta-Analysis]
Malik HS (2025). [PMID: 40918795](https://pubmed.ncbi.nlm.nih.gov/40918795/). *Cureus*. [Case Report / Case Series]
Rodrigues RF Sr (2025). [PMID: 40144429](https://pubmed.ncbi.nlm.nih.gov/40144429/). *Cureus*. [Case Report / Case Series]
Dequirez PL (2025). [PMID: 40858056](https://pubmed.ncbi.nlm.nih.gov/40858056/). *Auton Neurosci*. [Review / Meta-Analysis]
Lyu Q (2025). [PMID: 40355584](https://pubmed.ncbi.nlm.nih.gov/40355584/). *Sci Rep*. [Epidemiology / Natural History]
Panicker JN (2025). [PMID: 41293820](https://pubmed.ncbi.nlm.nih.gov/41293820/). *Neurourol Urodyn*. [Clinical Trial Publication]